Page last updated: 2024-11-12
ag 2000
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AG 2000: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 14234897 |
| SCHEMBL ID | 9814798 |
| MeSH ID | M0163564 |
Synonyms (7)
| Synonym |
|---|
| ag 2000 |
| 111712-16-4 |
| ag-2000 |
| 5h-pyrido(1',2':4,5)(1,2,4)thiadiazino(2,3-a)benzimidazol-13-ium, 4-methyl-3-(2,2,2-trifluoroethoxy)-, tetrafluoroborate(1-) |
| SCHEMBL9814798 |
| 6-methyl-5-(2,2,2-trifluoroethoxy)-9-thia-10,17-diaza-2-azoniatetracyclo[8.7.0.02,7.011,16]heptadeca-1(17),2(7),3,5,11,13,15-heptaene;tetrafluoroborate |
| ixvzbeywfwrnja-uhfffaoysa-n |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Relative resistance was not significantly changed by co-incubation with a non-cytotoxic dosage of these inhibitors." | ( Role of sodium pump systems to determine sensitivity to mitomycin C in non-small cell lung cancer cell lines. Bando, T; Fujimura, M; Kasahara, K; Matsuda, T; Nakatsumi, Y; Numata, Y; Shibata, K, ) | 0.13 |
| " Relative resistance was not altered by co-incubation with a non-cytotoxic dosage of AG-2000." | ( Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum(II) in non-small cell lung cancer cell lines. Bando, T; Fujimura, M; Kasahara, K; Matsuda, T; Nakatsumi, Y; Shibata, K, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||